DOT-PMB1-Header


As the pharmaceutical and biotech industries increasingly shift attention to biologics, much more attention is being paid to the prospect of membrane-bound proteins as drug targets for antibodies and other protein scaffolds. For the large GPCR and ion channel target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecule drugs and the potential for using antibodies for the targeted delivery of therapeutics.

The first meeting in the set, Antigen Optimization; Generation and Selection of Antibodies and Protein Scaffolds, offers a comprehensive examination of the range of methods available for producing appropriate membrane protein antigens, selecting the best screening methods for a specific target or target classes and how to develop and optimize the discovery and screening campaigns to identify functional antibodies. Part One also reviews other scaffold options, including single domain antibodies, as alternative therapeutic modalities for these targets.

Keynote Presentation: Selection of Membrane Protein Targets: GPCRs, Ion Channels and Transporters

Paul Insel, Ph.D., Professor, Pharmacology & Medicine, University of California, San Diego


IMMUNIZATION AND DISPLAY STRATEGIES FOR MEMBRANE PROTEINS

Computational Design of Epitope Scaffolds

William R. Schief, Ph.D., Professor, Immunology & Microbial Science, Scripps Research Institute; Director, Vaccine Design, International AIDS Vaccine Initiative

Cell-Free Expression of G-Protein Coupled Receptors: New Pipelines for Challenging Targets

Frank Bernhard, Ph.D., Group Leader, Institute of Biophysical Chemistry, Goethe University, Germany

Immunization Strategies for Antibody Generation against Multi-Spanning Proteins

Jane Seagal, Ph.D., Senior Scientist, AbbVie Bioresearch Center

Identification of Biased Antagonists by Screening Single Domain Antibodies against GPCRs in Lipoparticles

Mick Foley, Ph.D., Chief Scientific Officer, AdAlta, Australia

Case Study: VelocImmune Mice for Generation of Antibodies against Complex Membrane Protein Targets

Andrew Murphy, Ph.D., Vice President, Gene Discovery & Bioinformatics, Regeneron Pharmaceuticals

Discovery of MAbs against Difficult GPCRs, Ion Channels, and Transporters

Joseph Rucker, Ph.D., Vice President, Research & Development, Integral Molecular


DISCOVERY STRATEGIES FOR FUNCTIONAL ANTIBODIES AGAINST MEMBRANE PROTEIN TARGETS

Phage and Yeast Display for Discovery of Membrane-Bound Targets

Andrew M. Bradbury, Ph.D., MB, BS, Staff Scientist, Biosciences, Los Alamos National Laboratory

Protein Knockout Mice: A Novel in vivo Validation Approach for Membrane Targets

Stefan Dübel, Ph.D., Director, Institute of Biochemistry, Biotechnology and Bioinformatics, Technical University of Braunschweig, Germany

Engineering Conformation Selective Antibodies to Membrane Protein Complexes

Marcin Paduch, Ph.D., Technical Director, Synthetic Antibody & Crystallography Core Facility, Department of Biochemistry and Molecular Biology, Recombinant Antibody Network, The University of Chicago

Going Native: Direct High Throughput Screening of Soluble, Secreted mAbs Against Intact Target Cells

Karl Griswold, Ph.D., Associate Professor, Thayer School of Engineering, Dartmouth University


BEYOND ANTIBODIES: OTHER STRATEGIES FOR TARGETING MEMBRANE PROTEINS WITH BIOLOGICS

Affimers – Novel Scaffolds for Molecular Recognition of Membrane Targets

Darren Tomlinson, Ph.D., University Academic Fellow, University of Leeds, United Kingdom

Allosteric Nanobodies for Better Drug Discovery

Jan Steyaert, Ph.D., Director, Structural Biology Brussels Research Center, Vrije University Brussels, Belgium

Rational Design of Humanized Agonist Antibodies

Yong (Tiger) Zhang, Ph.D., Assistant Professor, Pharmacology & Pharmaceutical Sciences, University of Southern California

Targeting the FPR Receptor with a Long CDR3 Loop Scaffold

Matthew Gardener, Ph.D., Senior Scientist, Research, MedImmune

Identification of Potent Nanobodies against Ion Channels and GPCRs

Marie-Ange Buyse, Ph.D., Director, Discovery, Ablynx, Belgium



For questions or suggestions about the meeting, please contact:
Kent Simmons
Program Director
Cambridge Healthtech Institute
T: 207-869-9199
E: ksimmons@healthtech.com 

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

DOT Hub Icon

2014 Discovery on Target Brochure  


IPR_Micrombiome 


2014 BROCHURE 

 PREMIER SPONSORS 

Cellecta 

Molecular Sensing 

Rosa Drug Development Advisors
 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


Westin Boston Waterfront

HOTEL & TRAVEL 

Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
617.426.2000